SCHEMBL4861658

SCHEMBL4861658

O=C(CCBr)Nc1cccc2ncccc12

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.70
LMNA P02545 3/20 0.70
HTT P42858 2/20 0.70
SMN1; SMN2 Q16637 1/20 0.70
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
RECQL P46063 1/20 0.58
KDM4E B2RXH2 2/20 0.57
MAPT P10636 1/20 0.57
CLK1 P49759 1/20 0.57
P2RX7 Q99572 1/20 0.57
HDAC6 Q9UBN7 1/20 0.56
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
PABPC1 P11940 3/20 0.54
EIF4H Q15056 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
ATM Q13315 1/20 0.54
RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3319628 0.89 ALDH1A1 (0.64) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL21296583 0.88 ALDH1A1 (0.74) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL2639033 0.86 ALDH1A1 (0.70) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL9186736 0.86 ALDH1A1 (0.79) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL2639029 0.86 ALDH1A1 (0.70) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL30858814 0.83 ALDH1A1 (0.67) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL8402846 0.82 ALDH1A1 (0.74) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL6030652 0.82 ALDH1A1 (0.74) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL6030648 0.82 ALDH1A1 (0.74) ALDH1A1LMNAHTTSMN1; SMN2MEN1
SCHEMBL4865337 0.82 ALDH1A1 (1.00) ALDH1A1LMNAHTTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
EP-1567525-B1 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS INC (US) 2007-06-27 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ALDH1A1 245/4885LMNA 2835/4885HTT 2557/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ALDH1A1 281/4885LMNA 2300/4885HTT 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.